Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment

Tangying Lu and Dmitry I. Gabrilovich

Abstract

Tumor-associated myeloid cells are the major type of inflammatory cells involved in the regulation of antitumor immune responses. One key characteristic of these cells is the generation of reactive oxygen (ROS) and reactive nitrogen species (RNS) in the tumor microenvironment. Recent studies have shown the important role of ROS and RNS, especially peroxynitrite, in immune suppression in cancer. ROS and RNS are involved in induction of antigen-specific T-cell tolerance, inhibition of T-cell migration to the tumor site, and tumor cell evasion of recognition by cytotoxic T cells. In preclinical settings, a number of potential therapeutic agents showed activity in blocking ROS/RNS in cancer and in improving the efficacy of cancer immune therapy. A better understanding of ROS/RNS-associated pathways in myeloid cells will help to identify more specific and direct targets to facilitate the development of more effective immune therapy for cancer. Clin Cancer Res; 18(18); 4877–82. ©2012 AACR.

Background

Paradigms of modern tumor immunology

Several major paradigms currently determine therapeutic efforts in tumor immunology. The major paradigm states that an efficient antitumor immunity requires capture and processing of tumor-associated or tumor-specific antigens by professional antigen-presenting cells [dendritic cells (DC)] with subsequent presentation of these antigens in the lymph nodes to CD8⁺ cytotoxic T lymphocytes (CTL). Antigen presentation is associated with the activation of CD8⁺ T cells; among other things, it results in the upregulation of granzyme B (GrzB) necessary for the cytotoxic activity of CTLs and in the upregulation of certain chemokine receptors that facilitate T-cell migration to the tumor site. Once at the tumor site, T cells are able to recognize tumor cells expressing specific antigens and destroy them. Although this chain of events is observed in some experimental tumors, it is rare in cancer patients. Therefore, therapeutic efforts are focused on increasing the frequency of CTL-mediated tumor distraction by applying cancer vaccines, adoptively transferred antigen-specific T cells, inhibitors of check-point blockade (CTLA4, PD1) or other immune therapeutics (1). However, even in tumor-bearing mice, once tumors are established these interventions have relatively limited efficacy, and the rate of clinical responses in cancer patients, although encouraging, remains relatively low (2, 3). Appreciation of these facts has led to the establishment of another paradigm, which states that immune responses in cancer are inhibited. Large numbers of different factors have been implicated in this process, including regulatory T cells, myeloid cells, various soluble factors and cytokines, inhibitory molecules expressed by immune and tumor cells, and so forth (4–6). This has prompted a concerted effort to target specific molecules, with the goal of improving antitumor immune responses. However, the abundance of these inhibitory factors and the fact that most of them do not require antigen specificity to exert their suppressive effects are difficult to reconcile with the fact that in most cases neither tumor-bearing mice nor cancer patients are immune compromised (with the exception of terminal stages of the disease). T cells from the blood of cancer patients and from the spleens or lymph nodes of tumor-bearing mice have relatively strong responses to nonspecific stimuli such as lectins, antiCD3 antibody, and others. However, tumor-specific responses of these T cells are substantially inhibited (7–9). In contrast, T cells isolated from the tumor site in both patients and mice are profoundly suppressed, exhibiting dramatic changes in T-cell receptor (TCR) signaling, proliferation, and effector functions (10–12). This has resulted in the development of the third paradigm in tumor immunology: a compartmentalization of immune suppression in cancer. Immune deficiency at the tumor site is profound and antigen-independent, whereas in the periphery it is much more specialized with respect to tumor-associated antigens. Additional complications come from the fact that T-cell infiltration into solid tumors is limited by the effect of tumor stroma and other factors, discussed later in this article.

We recently proposed a new paradigm that may have direct implications for cancer immune therapy: Tumor
cells may resist recognition by potent CTLs in a way that does not affect immune suppression. This process is mediated by reactive oxygen species (ROS) and reactive nitrogen species (RNS) and is associated with tumor infiltration by myeloid cells (13).

**Myeloid cells in cancer and production of reactive oxygen species**

It is now clear that inflammation plays a major role in tumor progression (14). Myeloid cells are a major component of inflammatory reactions, and in recent years ample evidence has placed them at a prominent position in the regulation of tumor-associated immune suppression, tumor growth, and metastasis. Myeloid cells in cancer are represented by populations of mature cells (macrophages, granulocytes, and DCs), as well as by pathologically activated immature myeloid cells [myeloid-derived suppressor cells (MDSC)]. Some populations of mature myeloid cells in cancer may differ from their control counterparts by acquiring immune suppressive activity (15–19). MDSCs are the group of cells that are not present under normal conditions. They comprise a heterogeneous population of immature myeloid cells and myeloid progenitor cells. In healthy hosts, cells with the same phenotype are not immune suppressive and rapidly differentiate into mature myeloid cells. In cancer, these cells are expanded and activated, which results in the acquisition of potent immune-suppressive activity and the altered ability to differentiate. Based on the morphology and phenotype, in mice and cancer patients MDSCs can be subdivided into 2 major groups: polymorphonuclear MDSCs (PMN-MDSC) and monocytic MDSCs (M-MDSC; 20–23). M-MDSCs represent a population of pathologically activated monocytes with high levels of arginase 1 and inducible nitric oxide synthase [iNOS (Nos2)]. In the tumor microenvironment, these cells differentiate into immune-suppressive tumor-associated macrophages [TAM; ref. 24]. PMN-MDSCs represent a population of pathologically activated immature neutrophils and in culture rapidly differentiate into neutrophils (PMN). PMN-MDSCs have substantially higher levels of ROS and myeloperoxidase and reduced phagocytosis compared with PMN. PMN-MDSCs also contain fewer lysosomal enzymes than PMN and exhibit increased chemotaxis toward supernatants from human carcinomas (25, 26).

One of the predominant functions shared by all myeloid cells is the generation of ROS and RNS. In tumor-bearing hosts, ROS and RNS are the major mediators of myeloid cell–induced immune suppression (18, 27–30). In myeloid cells, NADPH oxidase (Nox1) is the primary producer of ROS. Nox1 reduces oxygen to superoxide anion (O$_2^-$). Superoxide anion then readily reacts with nitric oxide (NO) primarily produced by Nox2, and this results in the generation of peroxynitrite (ONOO$^-$). Peroxynitrite (PNT) is one of the most potent oxidants in the body. If not efficiently controlled by an antioxidant system, PNT can cause severe damage by oxidizing biologic molecules such as membrane phospholipids, nucleic acids, and proteins. In particular, PNT induces the nitration of 4 amino acids: tyrosine, cysteine, methionine, and tryptophan (31). Nitrotyrosine in tissues has been used as a marker of PNT activity (32).

The metabolism of l-arginine in myeloid cells is also associated with the production of ROS/RNS. l-arginine acts as a substrate for 2 enzymes, arginase 1 and Nos2. Arginase 1 converts l-arginine to urea and l-ornithine and directs the production of superoxide anion, whereas Nos2 causes the generation of high levels of NO. The cooperative effect of arginase 1 and Nos2 drives the production of PNT (33). PNT has been detected in many cancers, and high PNT levels in tumor tissues are associated with poor prognosis (34–38).

**Possible role of PNT in cancer**

At least 3 negative effects of myeloid cell–produced PNT have been shown in the tumor microenvironment (Fig. 1).

1. PNT can cause T-cell suppression and tolerance. Inside the tumor site, high levels of PNT induce the nitration of tumor-infiltrating lymphocytes and render these cells nonresponsive to various nonspecific stimuli (39). In the peripheral lymphoid organs, the level of PNT is much lower. It is produced by myeloid cells, primarily MDSCs, and it requires close cell–cell contact between MDSCs and T cells to affect T-cell function. Macrophages and neutrophils can also produce PNT, albeit at substantially lower levels than MDSCs, and potentially can contribute to this effect. PNT can induce T-cell tolerance via nitration of the TCRs and CD8 on the surface of T cells, rendering CD8$^+$ T cells unable to bind to peptide-MHC complexes (40). It is known that a single nitrated tyrosine can alter the recognition of MHC class I– and MHC class II–restricted peptides by CD8$^+$ and CD4$^+$ T cells, respectively (41, 42). CTLs with nitrated surface molecules showed no responses to the specific peptides, whereas nonnitrated CTLs responded normally to the peptide stimulation (9). However, after interaction with MDSCs, T cells retain their ability to respond to nonspecific stimuli.

2. PNT can affect tumor cells directly. We recently showed that PNT-treated tumor cells were resistant to lysis by tumor-specific CTLs. PNT treatment did not affect the expression of MHC class I on tumor cells, but it did dramatically reduce the binding efficiency of peptides to MHC class I molecules (13). This effect was primarily mediated by tumor-infiltrating MDSCs and to a lesser extent by macrophages. In several patient tumor types, including lung, breast, and pancreatic carcinomas, myeloid cells but not tumor cells were the main source of PNT (13). Similar results were observed in mouse tumor tissues. The inability of CTLs to kill tumor cells was not caused by inhibition of their functional activity and was observed even in experimental conditions where mice were treated with total body irradiation and adoptive T-cell transfer. Pharmacologic or genetic inhibition of ROS and PNT production in myeloid cells substantially reduced tumor cell resistance to CTLs. Moreover, inhibition of ROS and PNT...
production significantly enhanced the effect of cancer immune therapy (13). These data suggest that even if potent CTLs were generated by cancer vaccines or adoptive T-cell therapy, PNT-induced posttranslational modifications to peptide-MHC I complexes on tumor cells would render CTLs unable to recognize tumor-specific antigens and eliminate tumors.

3. PNT can affect T-cell migration to the tumor site. Molon and colleagues have showed that intratumoral production of PNT induces CCL2 chemokine nitration and inactivation, which blocks T-cell infiltration of the tumors (43). CCL2 is a chemoattractant for myeloid cells, activated T cells, and natural killer cells (44). Both human and mouse T cells were unable to migrate to the
nitrated CCL2. However, the migration of myeloid cells was not affected, which may explain why myeloid cells but not T cells are easily infiltrated tumors (43).

**Clinical–Translational Advances**

Because ROS and RNS play a major role in tumor-associated immune suppression and tumor progression, they have become an attractive target for therapeutic intervention. Several agents have shown therapeutic potential in preclinical studies, and some of them are currently being tested in clinical trials.

One group of agents is represented by synthetic triterpenoids. These compounds work through activation of the transcription factor Nrf2 (nuclear factor [erythroid derived]-like 2), which induces the upregulation of an array of antioxidant molecules, such as glutathione, thioredoxin, catalase, superoxide dismutase, and others (45). The most potent synthetic triterpenoid, CDDO-Me (C-28 methyl ester of 2-cyano-3,12-dioxooleana-1,9,10-dien-28-oic acid), showed a strong protective effect from inflammation-induced ROS in human neutrophils (46). Our group showed that in several tumor models CDDO-Me abrogated myeloid cell–induced immunosuppression. A similar effect was observed in some patients with pancreatic adenocarcinoma treated with CDDO-Me (47). That clinical trial, however, was not specifically designed to assess the function of these cells. CDDO-Me treatment also dramatically enhanced the therapeutic effect of total body irradiation and T-cell transfer in mice with established tumors. This effect was associated with a reduction of ROS and PNT levels at the tumor site. This prevented myeloid cell–induced nitration of MHC class I molecules on tumor cells, enabling tumor cells to present tumor-specific antigens and thereby increasing their susceptibility to killing by CTLs (13).

Nitroaspirins are a group of nonsteroid anti-inflammatory drugs coupled with a NO-releasing moiety. It has been shown that nitroaspirins are not only able to inhibit the production of inflammatory cytokines by mononuclear cells, but they are also effective at inhibiting ROS and RNS (48). They blocked inflammation-induced superoxide and Nox1 expression in smooth muscle cells and endothelial cells (49). Also, nitroaspirins suppress arginase 1 and Nos2 activity in myeloid cells. Their strong antiROS/RNS effect neutralized myeloid cell–induced T-cell dysfunction in mice with colon carcinoma and enhanced the therapeutic effect of anticancer immune vaccines (48).

[3-(Aminocarboxyl)]furoxan-4-yl][methyl] salicylate, a member of a recently described new class of NO-donor aspirin, containing the furoxan system, showed a strong ability to block the production of PNT \textit{in vivo} through the inhibition of arginase 1 and Nos2. It was found to be an effective adjuvant in adoptive cell therapy (43). The administration of this compound in tumor-bearing mice significantly increased tumor infiltration by CTLs. This effect was mediated by the reduced presence of nitrated CCL2 in tumors (43).

Phosphodiesterase-5 (PED5) inhibitors such as sildenafil and tadalafil, which are used in the clinic for noncancer-related conditions, were found to downregulate the expression of arginase 1 and Nos2 in myeloid cells. They were able to enhance the antitumor effect of CTLs in tumor-bearing mice, increase the infiltration and activation of CTLs inside the tumors, and improve the therapeutic effect of adoptive T-cell therapy (50). In limited settings of phase I clinical trial of patients with multiple myeloma and head and neck cancers, PED5 inhibitors restored lymphocyte proliferation, likely by blocking the suppressive effect of CD14$^+$ myeloid cells (50).

Cyclooxygenase 2 (COX-2) has been shown to induce the production of arginase 1 and ROS in tumor-infiltrating myeloid cells. COX-2 inhibitors such as SC58236, SC58125, and celecoxib were able to downregulate the expression of arginase 1, ROS, and PGE2, resulting in the improvement of antitumor T-cell effects and the efficacy of immunotherapy (51–53).

STAT3 plays an important role in cancer inflammation and in the suppression of antitumor immune responses. STAT3 is involved in the generation of ROS in myeloid cells by increasing Nox1 activity, either directly through upregulation of the expression of Nox1 subunits, or indirectly through upregulation of the expression of the calcium-binding proinflammatory proteins S100A9 and S100A8 (54, 55). Sunitinib, a tyrosine kinase inhibitor, showed substantial reversal of MDSC-mediated immune suppression (56). This effect could be mediated by blockade of STAT3 signaling activity (57).

In summary, ROS/RNS-induced modifications of proteins play a major role in the inability of the immune system to recognize and eliminate tumor cells, and most likely act as an important factor limiting the effect of immune therapies. Targeting ROS/RNS may substantially improve the effect of cancer immune therapy. Several compounds that do so have shown potent activity \textit{in vitro} and \textit{in vivo} in mouse tumor models, but their potential effects in cancer patients need to be determined. In many types of cancer, myeloid cells act as the major source of ROS and RNS in tumor tissues. Therefore, elimination of tumor-infiltrating myeloid cells could also contribute to a reduction in ROS/RNS. Although several mechanisms of ROS/RNS-mediated effects on the immune system in cancer have been suggested, the precise role of these mechanisms needs further elucidation.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Authors’ Contributions**

Conception and design: T. Lu, D.I. Gabrilovich

Development of methodology: T. Lu

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Lu

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Lu, D.I. Gabrilovich

Writing, review, and/or revision of the manuscript: T. Lu, D.I. Gabrilovich

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T. Lu, D.I. Gabrilovich

Study supervision: T. Lu, D.I. Gabrilovich
References


42. Hardy LL, Wick DA, Webb JR. Conversion of tyrosine to the inflammation-associated analog 3-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells. J Immunol 2008;180:5956–62.


Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment

Tangying Lu and Dmitry I. Gabrilovich


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-2939

Cited articles
This article cites 57 articles, 33 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/18/18/4877.full#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/18/18/4877.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.